Literature DB >> 31056963

SIRT1: a potential tumour biomarker and therapeutic target.

Bin Zhao1,2,3, Xin Li1,2,3, Liangfu Zhou1,2,3, Ye Wang1,2,3, Peng Shang1,3.   

Abstract

SIRT1, which is highly homologous to yeast silent information regulator 2, has recently garnered tremendous attention because of its various regulatory effects in several pathological conditions. Numerous studies have found that SIRT1 is highly expressed in a broad range of tumours compared with the paracancerous tissue. However, the role of SIRT1 in malignancies has yet to be systematically elucidated, and its use as a promising biomarker or therapeutic target for tumours has not been well-reported. Herein, we focus on the roles of SIRT1 in cancers and summarise the potential use of SIRT1 as a promising tumour biomarker or therapeutic target.

Entities:  

Keywords: 

Mesh:

Substances:

Year:  2019        PMID: 31056963     DOI: 10.1080/1061186X.2019.1605519

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  5 in total

1.  Additive pharmacological interaction between sirtuin inhibitor cambinol and paclitaxel in MCF7 luminal and MDA-MB-231 triple-negative breast cancer cells.

Authors:  Anna Wawruszak; Estera Okon; Ilona Telejko; Arkadiusz Czerwonka; Jarogniew Luszczki
Journal:  Pharmacol Rep       Date:  2022-07-28       Impact factor: 3.919

2.  Sirt1 gene confers Adriamycin resistance in DLBCL via activating the PCG-1α mitochondrial metabolic pathway.

Authors:  Zhen Zhou; Dan Ma; Peifan Li; Ping Wang; Ping Liu; Danna Wei; Jun Wang; Zhong Qin; Qin Fang; Jishi Wang
Journal:  Aging (Albany NY)       Date:  2020-06-22       Impact factor: 5.682

3.  B7‑H3 promotes the epithelial‑mesenchymal transition of NSCLC by targeting SIRT1 through the PI3K/AKT pathway.

Authors:  Haixiu Liao; Meng Ding; Nannan Zhou; Ying Yang; Liwen Chen
Journal:  Mol Med Rep       Date:  2022-01-14       Impact factor: 2.952

4.  Targeting nicotinamide N-methyltransferase overcomes resistance to EGFR-TKI in non-small cell lung cancer cells.

Authors:  Xi Liu; Yuanfeng Huang; Jun Wang; Pan Li; Minqiang Yang; Shanshan Zeng; Danyang Chen; Qian Wang; Hao Liu; Kai Luo; Jin Deng
Journal:  Cell Death Discov       Date:  2022-04-06

5.  MDM2-dependent Sirt1 degradation is a prerequisite for Sirt6-mediated cell death in head and neck cancers.

Authors:  Jung Je Park; Young-Sool Hah; Somi Ryu; So Young Cheon; Seong Jun Won; Jong Sil Lee; Jeong Seok Hwa; Ji Hyun Seo; Hyo Won Chang; Seong Who Kim; Sang Yoon Kim
Journal:  Exp Mol Med       Date:  2021-03-16       Impact factor: 8.718

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.